THE BIOSIMILARS LANDSCAPE

This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

As featured in the 2023 Biosimilars Report, here are highlights of some of the most noteworthy milestones in the development and adoption of biosimilars from ...

Biologics and Biosimilars Landscape: IP, Policy, and Market ...

Prior to its approval, Tofidence™ was subject to BPCIA litigation filed by Genentech against Biogen and Bio-Thera in July 2023. The parties ...

Understanding the Biosimilar Landscape - Univera For Business

Biosimilars are biologic drugs that are “highly similar” and “clinically equivalent” to another biologic “reference” product already approved by the US Food ...

Navigating the Biosimilar Frontier: Opportunities and Challenges in ...

The Current Landscape of Biosimilars. Biosimilars are designed to replicate the therapeutic effects of original biologics, but they deviate ...

The regulatory landscape of biosimilars: WHO efforts and progress ...

USA-approved filgrastim as the first biosimilar product in 2015. Since then a total of 23 biosimilars have been approved. Three insulin products (2 glargine and ...

The biosimilars landscape

Global sales of biosimilars have more than doubled each year since 2007, and had reached more than US$234 million in 2010, see Figure 1. EPOs take the major ...

In this white paper, we delve into the concept of biosimilars, their distinctions from generics, their impact on reimbursement policies, and the challenges and ...

Navigating the Biosimilar Landscape: What to watch out in 2024 and ...

In 2024, we expect increased manufacturing market share from BRICS, policies creating a favorable environment for biosimilars, intensified competition, and ...

Masterclass: Navigating the Biosimilars Landscape - McKesson

Resources to help you navigate every step of the biosimilar journey so you can achieve more.

Current Landscape of Biosimilar Use in US Healthcare Space

Dr Humphreys drives a conversation scoping the biosimilar landscape and available treatment options.

The chemical, manufacturing and control (CMC) strategy to ensure structural and functional biosimilarity is the most crucial step. A successful CMC strategy ...

Developments and Considerations in the Biosimilar Landscape

The biosimilar landscape has experienced significant evolution in recent years. In 2023, the blockbuster drug Humira,.

The current status of the biosimilars landscape in China

As of September 2023, China has approved a total of 31 antibody-based biosimilars (see Table 1). These include 10 versions of Bevacizumab, 7 versions of ...

Evolving Biosimilar Landscape

Learn how biosimilars and biologics have been used to treat different life-threatening & chronic diseases, such as cancers and diabetes, & their potential ...

This article explores the complexities of biosimilars, including their development process, regulatory challenges, economic impact, and future prospects.

Drug Solutions Podcast: The Biosimilars Landscape - PharmTech

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not ...

2021 BIOSIMILARS LANDSCAPE. 2021 BIOSIMILARS LANDSCAPE. Figure 1. FDA approved biosimilars. Biosimilars to be launched; all others are currently marketed.

This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation

Biosimilar Drugs & Products - McKesson

... biosimilar adoption. As the biosimilar landscape continues to evolve, we can expect to see more biosimilar treatment options for more conditions. McKesson ...